Cohen Capital Management Inc. Purchases 1,984 Shares of Moderna, Inc. (NASDAQ:MRNA)

Cohen Capital Management Inc. lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 22.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,938 shares of the company’s stock after purchasing an additional 1,984 shares during the quarter. Cohen Capital Management Inc.’s holdings in Moderna were worth $455,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. Arkadios Wealth Advisors lifted its position in Moderna by 2.2% during the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock valued at $764,000 after buying an additional 243 shares during the period. Knuff & Co LLC increased its stake in shares of Moderna by 5.4% in the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after acquiring an additional 244 shares in the last quarter. Stephens Inc. AR lifted its position in Moderna by 7.9% during the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after acquiring an additional 245 shares during the period. Allworth Financial LP boosted its stake in Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after acquiring an additional 281 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

NASDAQ MRNA opened at $35.53 on Friday. The stock has a market capitalization of $13.67 billion, a price-to-earnings ratio of -3.83 and a beta of 1.59. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The business’s fifty day moving average price is $38.04 and its 200-day moving average price is $52.66.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by insiders.

Analyst Ratings Changes

MRNA has been the subject of several recent research reports. Leerink Partners lowered their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Berenberg Bank boosted their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Wolfe Research began coverage on Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price on the stock. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Monday, November 18th. Finally, JPMorgan Chase & Co. set a $45.00 price objective on shares of Moderna in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.